IL1B and myocardial infarction: The IL-1β neutralising antibody canakinumab, tested in the CANTOS trial in post-MI patients, significantly reduced recurrent cardiovascular events, providing proof-of-concept that targeting inflammasome outputs benefits patients (22, 23).